Skip to content
Search

Latest Stories

ECG Healthcare launches new PGD and medical advice service

ECG has launched a new ‘simple and straightforward’ Patient Group Direction (PGD) service for pharmacists working in primary care, together with a service which offers direct access to an NHS Consultant for medical advice to offer robust safeguarding as and when needed.

Taking on more clinical services with the PGDs can feel daunting and a big responsibility for healthcare professionals. ECG’s new medical advice service (for anyone purchasing their PGDs) will offer pharmacists the opportunity to call and speak to a clinical member of the ECG team who will triage the calls and support them.


If required, the call will be connected to an experienced NHS Consultant to offer immediate medical advice. The service will start with a Monday-Friday 08:30-16:30hrs provision with an option to increase to 24 /7 for those working out of hours. This is inclusive in the PGD pricing offer.

ECG has been the market leader in providing vaccination training to pharmacists since 2004, providing robust knowledge and clinical skills to enable pharmacists to develop their private and NHS commissioned vaccination services (such as flu and covid). By developing their close working relationship with all of the multiples, many smaller chains, membership groups and independents over the years, ECG has continued to further consolidate their ‘one stop shop’ approach to supporting the sector.

ECG wants to offer this sector choices in the level of guidance and support that the individual healthcare professionals feel they need to offer safe care to patients.

With several PGD providers covering the market, healthcare professionals will have the choice of how ‘simple’ they want their PGD to be, or if they feel they need more guidance through software solutions. With either option, we need to continue to ensure the quality and safety of the services offered in any setting and access to expert medical advice will offer a further layer of safe practice.

Jane Lambert, CEO of ECG Healthcare commented: “We love supporting community pharmacy and we hope that by offering an alternative service, pharmacists will be able to select what is right for their level of competence and confidence in the clinical services they offer.”

She added: “There is an appetite for some to take on more clinical diagnosis and treatment within the community. This service, along with access to expert medical advice, without delay, will enable further development of services and help us to improve patient care.”

Carolynne Allan, director of Pharmacy Services for ECG said: “From past experience as a community pharmacist, PGDs can appear complicated and sometimes confusing. With this in mind, our PGDs have been written in a simple, user-friendly way to enable healthcare professionals to make decisions regarding safe supply of medication. We hope this simplicity will create confidence to provide services to patients at a time when the NHS really needs our help.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less